Navigation Links
Dr. Paul Korner Promoted to Senior Vice President of Ferring International PharmaScience Center U.S.
Date:3/17/2009

PARSIPPANY, N.J., March 17 /PRNewswire/ -- Ferring Pharmaceuticals Inc., a specialty pharmaceutical company, announces the promotion of Paul Korner, M.D., M.B.A. to Senior Vice President of the Ferring International PharmaScience Center U.S. (FIPCUS), the drug development subsidiary for Ferring Pharmaceuticals Inc. Dr. Korner was formerly Vice President, Medical Affairs for Ferring's Infertility, Orthopaedics, Urology, and Gastroenterology therapeutic areas, as well as Product Safety. In his new role, Dr. Korner will be responsible for the clinical management of U.S. drug development.

"Dr. Korner has made tremendous strides in his first six months with Ferring, and is exceptionally well qualified to lead the clinical programs at our PharmaScience Center," said Wayne Anderson, President and CEO of Ferring Pharmaceuticals Inc., and Chairman of FIPCUS. "He will oversee the drug development of our rich pipeline of products as we continue our quest to achieve rapid new drug approvals by identifying, improving and commercializing late-stage or marketed products in our clinical specialty areas."

Dr. Korner joined Ferring in 2008 with a broad range of experience in medical affairs, clinical development, management and business development. During his first six months at Ferring, he restructured the Medical Affairs and Product Safety departments, created a Medical Information department, and was instrumental in the pre-launch activities for newly approved degarelix for injection.

Prior to joining the company, Dr. Korner was Vice President of Medical Affairs, Women's Healthcare at Bayer HealthCare Pharmaceuticals, where his group supported the U.S. Women's Healthcare business unit, and managed medical experts supporting Phase II and III development projects. He has also served as Executive Director of Medical Affairs, Female Healthcare at Berlex Laboratories, Inc., and Senior Director of Clinical Research and Development, Women's Health and Bone Repair for Wyeth Research.

Dr. Korner is a board certified obstetrician and gynecologist. He received his M.D. from Loyola University, Stritch School of Medicine near Chicago. He also holds an M.B.A. from the Michael J. Coles College of Business at Kennesaw State University in Georgia.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals offers a line of urology, orthopaedic and infertility products in the U.S. market. They include: EUFLEXXA(R) (1% sodium hyaluronic acid), BRAVELLE(R) (urofollitropin for injection, purified), MENOPUR(R) and REPRONEX(R) (menotropins for injection, USP), Novarel(R) (chorionic gonadotropin for injection, USP), ENDOMETRIN(R) (progesterone) Vaginal Insert, ACTHREL(R) (corticorelin ovine triflutate for injection), PROSED(R) DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), Degarelix for injection, and DESMOPRESSIN.

Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology, and infertility. For complete prescribing information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.


'/>"/>
SOURCE Ferring Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
2. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
3. Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Brothers Movie to Be Filmed About Him
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
6. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
7. Senior Research Analyst Richard Evans Joins AVOS Life Sciences
8. Schering-Plough Announces Pricing of Senior Notes Offering
9. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
10. Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference
11. Solazyme Announces New Senior Vice President of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... (PRWEB) , ... May 22, 2017 , ... ... and Photonics 2017 in San Diego, California, this August will feature high-level ... fuels, and autonomous vehicles. , SPIE Optics and Photonics, the largest multidisciplinary optical ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... as Vice President of Clinical Operations. She brings years of expertise in ... Therapeutics. From her professional foundation as a licensed occupational therapist, through a variety ...
(Date:5/23/2017)... ... 23, 2017 , ... Customers often prefer PLC and ... again. METTLER TOLEDO has released two new videos that show how they have ... the ACT350 into Siemens and Allen Bradley PLCs is easy and fast. ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... is exhibiting in booth B2 at the Association for Pathology Informatics Annual ... , In addition to demonstrating its Cancer Diagnostic Cockpit and Consultation Portal, Inspirata ...
Breaking Biology Technology:
(Date:4/13/2017)... 2017 UBM,s Advanced Design and Manufacturing event ... emerging and evolving technology through its 3D Printing and ... alongside the expo portion of the event and feature ... focused on trending topics within 3D printing and smart ... event will take place June 13-15, 2017 at the Jacob ...
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
Breaking Biology News(10 mins):